{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T02:03:32Z","timestamp":1790301812437,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T00:00:00Z","timestamp":1675987200000},"content-version":"am","delay-in-days":374,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales d'Endocrinologie"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.ando.2021.11.006","type":"journal-article","created":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T12:05:50Z","timestamp":1638533150000},"page":"59-62","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["The heart, an endocrine gland: Natriuretic peptides"],"prefix":"10.1016","volume":"83","author":[{"given":"Madleen","family":"Lemaitre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Jannin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Chevalier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Christine","family":"Vantyghem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ando.2021.11.006_bib0125","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/s41569-020-0381-0","article-title":"Cardiac natriuretic peptides","volume":"17","author":"Goetze","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.ando.2021.11.006_bib0130","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.lpm.2017.12.002","article-title":"Atrial natriuretic hormones and metabolic syndrome: recent advances","volume":"47","author":"Benomar","year":"2018","journal-title":"Presse Med"},{"key":"10.1016\/j.ando.2021.11.006_bib0135","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1172\/JCI59701","article-title":"Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes","volume":"122","author":"Bordicchia","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ando.2021.11.006_bib0140","doi-asserted-by":"crossref","first-page":"19178","DOI":"10.1038\/s41598-019-55680-z","article-title":"Insulin\/glucose induces natriuretic peptide clearance receptor in human adipocytes: a metabolic link with the cardiac natriuretic pathway","volume":"9","author":"Spannella","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.ando.2021.11.006_bib0145","doi-asserted-by":"crossref","first-page":"H358","DOI":"10.1152\/ajpheart.00704.2012","article-title":"Natriuretic peptides and cGMP signaling control of energy homeostasis","volume":"304","author":"Moro","year":"2013","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.ando.2021.11.006_bib0150","first-page":"86","article-title":"Recent data on the regulation of lipolysis by catecholamines and natriuretic peptides","volume":"63","author":"Lafontan","year":"2002","journal-title":"Ann Endocrinol (Paris)"},{"key":"10.1016\/j.ando.2021.11.006_bib0155","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1373\/clinchem.2019.306175","article-title":"A View on the interrelationship between obesity and natriuretic peptide measurements: can dysregulation in pro-b-type natriuretic peptide glycosylation explain decreased b-type natriuretic peptide concentrations in obese heart failure patients?","volume":"65","author":"Semenov","year":"2019","journal-title":"Clin Chem"},{"key":"10.1016\/j.ando.2021.11.006_bib0160","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/nm971","article-title":"Kazuwa Nakao Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway","volume":"10","author":"Akihiro","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.ando.2021.11.006_bib0165","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1093\/eurheartj\/ehab627","article-title":"The ESC Guidelines on heart failure, sacubitril-valsartan in resistant hypertension, and new therapeutic targets in myocardial hypertrophy","volume":"42","author":"Crea","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ando.2021.11.006_bib0170","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1253\/circj.CJ-20-1104","article-title":"Effects of age, sex, and obesity on N-Terminal Pro B-Type natriuretic peptide concentrations in the general population","volume":"85","author":"Hyo-In","year":"2021","journal-title":"Circ J"},{"key":"10.1016\/j.ando.2021.11.006_bib0175","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1093\/clinchem\/hvaa308","article-title":"Plasma clearance of B-type natriuretic peptide (BNP) before and after bariatric surgery for morbid obesity","volume":"67","author":"Kian Keong Poh","year":"2021","journal-title":"Clin Chem"},{"key":"10.1016\/j.ando.2021.11.006_bib0180","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/ki.2008.418","article-title":"Corin: new insights into the natriuretic peptide system","volume":"75","author":"Qingyu Wu","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.ando.2021.11.006_bib0185","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S0140-6736(20)31541-5","article-title":"Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial","volume":"396","author":"Ravi Savarirayan","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ando.2021.11.006_bib0190","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1056\/NEJMoa1813446","article-title":"C-Type natriuretic peptide analogue therapy in children with achondroplasia","volume":"381","author":"Ravi Savarirayan","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2021.11.006_bib0195","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/j.jacc.2021.01.033","article-title":"EMPEROR-reduced trial committees and investigators. Empagliflozin in patients with heart failure, reduced ejection fraction, and volume overload: EMPEROR-Reduced Trial","volume":"77","author":"Packer","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ando.2021.11.006_bib0200","article-title":"EMPEROR-preserved trial study group.effect of empagliflozin on worsening heart failure events in patients with heart failure and a preserved ejection fraction: the EMPEROR-preserved trial","author":"Packer","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.ando.2021.11.006_bib0205","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1161\/CIRCULATIONAHA.121.053659","article-title":"Dapagliflozin and recurrent heart failure hospitalizations in heart failure with reduced ejection fraction: an analysis of DAPA-HF","volume":"143","author":"Jhund","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.ando.2021.11.006_bib0210","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12933-019-0877-2","article-title":"Canagliflozin for Japanese patients with chronic heart failure and type II diabetes","volume":"18","author":"Sezai","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.ando.2021.11.006_bib0215","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1016\/j.jacc.2020.09.004","article-title":"Effects of canagliflozin on amino-terminal pro-B-type natriuretic peptide: implications for cardiovascular risk reduction","volume":"76","author":"James","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ando.2021.11.006_bib0220","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.ando.2020.07.1113","article-title":"The plasma levels of atrial natriuretic peptide and brain natriuretic peptide in type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor","volume":"81","author":"Feng","year":"2020","journal-title":"Ann Endocrinol (Paris)"},{"key":"10.1016\/j.ando.2021.11.006_bib0225","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1111\/dom.14387","article-title":"Association of estimated plasma volume and weight loss after long-term administration and subsequent discontinuation of the sodium-glucose cotransporter-2 inhibitor tofogliflozin","volume":"23","author":"Yasuhiro Matsubayashi","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ando.2021.11.006_bib0230","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1111\/dom.14377","article-title":"Dapagliflozin reduces systolic blood pressure and modulates vasoactive factors","volume":"23","author":"Ghanim","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ando.2021.11.006_bib0235","article-title":"Effect of sacubitril\/valsartan combined with dapagliflozin on long-term cardiac mortality in heart failure with reduced ejection fraction","volume":"24","author":"Karabulut","year":"2021","journal-title":"Angiology"},{"key":"10.1016\/j.ando.2021.11.006_bib0240","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.jacc.2020.09.538","article-title":"Limitations of natriuretic peptide levels in establishing SGLT-2 inhibitors for heart failure care","volume":"76","author":"Velazquez","year":"2020","journal-title":"J Am Coll Cardiol"}],"container-title":["Annales d'Endocrinologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000342662101101X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000342662101101X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T22:53:54Z","timestamp":1757717634000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000342662101101X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S000342662101101X"],"URL":"https:\/\/doi.org\/10.1016\/j.ando.2021.11.006","relation":{},"ISSN":["0003-4266"],"issn-type":[{"value":"0003-4266","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The heart, an endocrine gland: Natriuretic peptides","name":"articletitle","label":"Article Title"},{"value":"Annales d'Endocrinologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2021.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}